IMDX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
IMDX is not a good buy right now for a Beginner long-term investor with $50,000-$100,000 to deploy. The stock has some positive elements, including a recent analyst target increase, a Buy rating, and a potential FDA submission catalyst, but the current business fundamentals are still weak with falling revenue, widening net losses, and negative EPS. Technically, the stock is neutral-to-mildly constructive, but not strong enough to justify an immediate buy without a clearer breakout or fundamental improvement. Since there is no strong proprietary buy signal today, the better call is to hold and wait.
IMDX is trading pre-market around 3.97-4.01, slightly above the pivot at 3.884 and below resistance at 4.373. The MACD histogram is positive at 0.122 but contracting, which suggests bullish momentum is fading rather than accelerating. RSI_6 at 58.373 is neutral, and the moving averages are converging, pointing to a consolidation phase rather than a strong trend. The near-term pattern data also suggests limited upside in the next day and only modest gains over the next week/month. Overall, the chart is not bearish, but it is not strong enough to support an aggressive long-term entry right now.
Lake Street raised its price target to $12 from $8 and kept a Buy rating, which is a strong positive analyst catalyst. The analyst also expects an FDA submission for GraftAssureDx in the coming weeks, which could re-rate the stock if executed well. The company also recently completed a $26M offering, improving cash visibility ahead of a potential approval later this year. Gross margin improved sharply year over year, showing some operational efficiency progress.
No news was released in the recent week, so there is no immediate sentiment boost from current headlines. Revenue in Q4 2025 fell 23.35% year over year, net income worsened to -$22.955M, and EPS dropped 62.50%, showing that the core financial picture remains weak. Hedge funds and insiders are both neutral, which means there is no meaningful buying conviction from informed holders. There is also no recent congress trading data and no evidence of politician or influential figure buying or selling the stock.
Latest quarter: 2025/Q4. Revenue declined to $1.139M, down 23.35% YoY, which is a negative growth trend. Net income fell to -$22.955M, down 31.50% YoY, and EPS dropped to -$0.72, down 62.50% YoY, showing worsening profitability. The only clear improvement was gross margin, which increased to 43.55%, up 8.77% YoY. This suggests better unit economics, but overall quarterly financial performance remains weak.
Recent analyst trend is positive: Lake Street raised the price target from $8 to $12 and maintained a Buy rating. The tone is constructive because the firm believes upcoming FDA submission timing could be a catalyst. Wall Street's pro view is centered on regulatory upside, improving cash from the recent offering, and margin improvement. The con view is that revenue is declining, losses are still large, and the company is not yet demonstrating durable operating growth.
